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The case of a 28-year-old female patient is reported with aIntroduction
Crohn’s disease (CD) is a regional enteritis that affects the ter-
minal ileum, but has the potential of involving any segment
of the gastrointestinal tract of the patient.1
The etiology of CD is unknown, but several proven risk
factors exist such as family history, smoking, oral contra-
ceptives, diet and ethnicity. The combination of risk factors,
and aberrant autoimmune response in the intestinal mucosa
with endothelial dysfunction lead to digestive tract malfunc-
tioning. Disease manifestations are heterogeneous but most
patients present with abdominal pain, diarrhea sometimes
with blood, weight loss, fever and perianal lesions. Up to 30%
of CD patients have ﬁstulae.
The current treatment is not ideal. Therapy generally
involves steroids and anti-tumor necrosis factor alpha (TNF)
blockers but about one-third of patients fail to respond (pri-
2mary non-responders) and 10% of patients do not tolerate
or are primary non-responders to all drugs used. One-third
of responders to anti-TNF treatment show transient loss
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reserved.of response (secondary non-responders).3 Severe cases may
require partial resection of a segment of bowel, possibly total
colectomy with the placement of stoma bags for feces when
the disease affects the rectum.1,4 Despite new therapeutic
strategies, the number of surgeries remains stable.5 Many
patients evolve well with this approach; however, sometimes
the disease persists, becoming refractory and progressive,
dramatically affecting the quality of life (QoL) of patients
including risk of death.6
Thus, new treatment options are needed. Recently, cell
therapies with T lymphocytes, tolerogenic dendritic cells and
both hematopoietic and mesenchymal stem cells, have started
to be researched.7
Case  reporto José do Rio Preto, SP, Brazil.
four-year diagnosis of CD. She had been submitted to the
resection of a 40-cm segment of bowel due to stenosis. She was
refractory to treatment using corticosteroids, azathioprine,
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights

















































Figure 1 – (A) Serpiginous ulcerations, with fold
convergence, intervening ridges of swollen congested
mucosa and central ﬁbrinous exudate. (B) White scaring
and scar retraction seven months after autologousrev bras hematol hemot
nﬂiximab and adalimumab. The patient suffered repeated
pisodes of abdominal pain, mucus bloody diarrhea, weight
oss, depression and psychosis.
She had constant, but migratory, joint pain since diagno-
is. Moreover, swelling of wrists and skin lesions of all limbs
haracteristic of psoriatic arthritis were apparent at the ﬁrst
xamination.
An anatomopathological study of the antrum and cor-
us gastricum by endoscopy and colonoscopy showed slight
eactive and vascular congestion and an investigation of Heli-
obacter pylori was negative.
Active ileitis and proctitis were observed in the ileoce-
al valve, right colon, left colon and rectum with extensive
reas of ulceration and histologic evidence of inﬂammatory
owel disease compatible with CD. Additionally, changes in
he regenerative architecture were observed as were epithe-
ioid granulomas with multinucleated giant cells but without
aseous necrosis (Figure 1).
Autologous hematopoietic stem cell transplantation
HSCT) was indicated. The procedure was only performed
fter a court order as this procedure is not authorized by
he Brazilian healthcare system and after approval by the
ospital Medical Ethics Committee.
Prior to starting the HSCT regimen, the patient was sub-
itted to physical and standard laboratory evaluations.
The Crohn’s Disease Activity Index (CDAI) was more  than
50 (severely ill) with large ulcerations and involvement of
ore  than 35% of the surface.8 Her Montreal classiﬁcation was
2/L3/B2 with major extraintestinal manifestations includ-
ng iritis two years previously and polyarticular arthritis. The
atient’s QoL was determined using the QoL questionnaire –
hort Form 36 (QoL SF-36).
The patient was mobilized with cyclophosphamide
60 mg/kg) and granulocyte colony stimulating factor
10 mg/kg) for seven days with 4.59 × 106 CD34+ cells/kg
eing collected from peripheral blood in two leukapheresis
essions (Hemonetics MSC+ USA). The hematopoietic cells
ere cryopreserved in dimethyl sulfoxide and stored in the
apor phase of liquid nitrogen until transplantation.
The patient was then admitted in the bone marrow trans-
lant unit where she underwent a prophylaxis regimen for
arasitic, bacterial, and fungal agents and Pneumocystis carinii.
iproﬂoxacin was administered for partial bowel decontami-
ation and the patient underwent hyperhydration and mesna
rophylaxis to prevent hemorrhagic cystitis. The condition-
ng regimen consisted of cyclophosphamide (50 mg/day) and
abbit anti-thymocyte globulin (Thymoglobulin, Genzyme –
.25 mg/kg/day) for four days.
The neutrophils dropped below 0.5 × 109 cells/L after only
ve days and engraftment occurred on the 10th day after infu-
ion. The patient was discharged on Day +12 and the only tox-
city reported was mild mucositis. Transfusion requirements
ere only two bags of irradiated concentrated red blood cells.
All the symptoms of the disease such as diarrhea and
bdominal and joint pain disappeared in the mobilization
eriod before ASCT.Cytomegalovirus (CMV) reactivation occurred on Day +20,
nd was treated with ganciclovir (5 mg/kg/day) for 12 days.
Three months after the HCST, the patient suffered
 herpes zoster infection of the back; this improvedhematopoietic stem cell transplantation.
within 15 days using speciﬁc local and systemic medica-
tions.
The results of a second colonoscopy six months after HSCT
were normal (Figure 2). One year after the procedure the
patient is well, without any symptoms with a CDAI < 150 (clin-
ical remission) and consequent improvements in QoL.
DiscussionEven though high morbidity and mortality rates were asso-
ciated with autologous HSCT to treat autoimmune diseases,
138  rev bras hematol hemoter.
Figure 2 – (A) Ileocolic anastomosis with intense
hyperemia, linear ulcers, deformities and spontaneous
friability. (B) The same site after autologous hematopoietic
stem cell transplantation showing complete mucosal
r
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complication rates have dropped due to experience in this
procedure. Similar to several other autoimmune diseases, risk
should outweigh the possibility of cure.9 Thus, HSCT is a feasi-
ble procedure, which, when incorporated to treat autoimmune
diseases, can provide good results with clinical remission. The
indication of HSCT is based on immune system ablation fol-
lowed by regulation and regeneration of the T-cell repertoire
via immune system resetting.10,11
Reports of HSCT for CD are not as common as some
other diseases including multiple sclerosis and systemic
sclerosis. Both autologous and allogeneic modalities have
been described with consistent clinical and long term
remission.12–14
The indications of the procedure are not well established.
However, HSCT should be considered in speciﬁc severe and
refractory cases when surgical resection is indicated and in
patients with a history of resection. In the current case, the
criteria of the European Group for Bone Marrow Transplant
(EBMT) were followed as described below.15,16
Autologous HSCT should be indicated:• In severe cases that do not respond to treatment with
immunosuppressive agents and anti-tumor necrosis fac-
tors; 2 0 1 5;3  7(2):136–139
• In active or refractory CD that is not controlled by immuno-
suppressants or biological agents;
• When there is an indication of surgery but with a risk of
small bowel syndrome;
• In refractory colonic disease with perianal lesions when
coloproctectomy with deﬁnitive implantation of the stoma
is not accepted by the patient.
In this case the hematologic and gastrointestinal toxic-
ity was minimal. Symptoms such as abdominal pain, profuse
bloody diarrhea, joint pain and cutaneous lesions disappeared
either during the conditioning regimen or soon after HSCT.
The clinical remission described in this case has remained
until the present time, one year after the procedure.
Global blockade of immune cells such as T-cells has failed
in CD but therapies using mesenchymal, hematopoietic and
adipose tissues are promising.17 The best idea seems to be
autologous non-myeloablative HSCT. In the largest series so
far, all 24 patients went into remission. Although a large
number of patients relapse and require treatment after trans-
plantation, according to Baumgart et al. the percentages of
patients in remission, steroid-free or medication-free ﬁve
years after transplant were at least 70%, 80% and 60%,
respectively.17
HSCT for CD in Brazil is not a procedure authorized by the
National Health System or health insurance agencies. HSCT
in these situations is restricted to cases enrolled in clinical
trials, which do not exist in Brazil as there is no regulation for
compassionate treatment. This procedure was possible due to
a court order obtained by the patient, because of the severity of
the case and compliance to EBMT criteria. There are no other
reports of the use of HSCT for CD in Brazil but this procedure
seems to be safe and well tolerated by the patient.
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